托皮拉的营销后安全监测:基于FDA不良事件报告系统数据库的信号检测和分析研究
Kai Lin1,2, Mengjiao He1, Zuoqi Ding1
1School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, China.
Journal of evidence-based medicine
|December 18, 2024
概括
这项研究分析了FDA对托皮拉不良事件的数据,确定了药物标签上没有的严重风险,如低血压症和功能障碍,突出了需要警监测的需要.
科学领域:
- 药物监督 药物监督 药物监督
- 药品安全 药品安全
- 监管科学 监管科学
背景情况:
- 托皮拉被广泛用于和偏头痛.
- 了解其不良事件概况对于患者安全至关重要.
研究的目的:
- 使用FDA不良事件报告系统数据调查与托皮拉玛相关的不良事件.
- 识别目前未在药品标签上列出的潜在安全信号.
主要方法:
- 分析了从开始到2024年第一季度的12,168份不良事件报告.
- 使用报告概率比率,MHRA和BPCNN用于信号检测.
- 使用MedDRA v27.0进行分类事件,并将信号与药物标签进行比较.
主要成果:
- 在15个器官系统类别中确定了244个积极信号.
- 检测到21种未在标签上显示的严重不良反应,包括低血压症和脊柱裂变.
- 突出显示的信号是管功能障碍,脑膜炎,透性脱髓化综合征和阿诺德-奇亚里形.
结论:
- 确定了几种意想不到的严重不良反应信号.
- 这些发现支持了对托皮拉使用的持续警和监测的需要.
- 强调更新药物标签以新出现的安全数据的重要性.
相关概念视频
Pharmacovigilance
773
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
773
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Clinical Trials: Overview
2.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K
Antiepileptic Drugs: Glutamate Antagonists
280
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
280
Antiepileptic Drugs: Potassium Channel Activators
143
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
143
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
245
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
245


